6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00006077 (ClinicalTrials.gov) | August 2000 | 4/8/2000 | Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease | Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease | Parkinson's Disease | Drug: NS2330;Drug: Levodopa and Domperidone | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 50 | Phase 2 | United States |